f Metallo--lactamase (MBL) genes confer resistance to virtually all -lactam antibiotics and are rapidly disseminated by mobile genetic elements in Gram-negative bacteria. MBLs belong to three different subgroups, B1, B2, and B3, with the mobile MBLs largely confined to subgroup B1. The B3 MBLs are a divergent subgroup of predominantly chromosomally encoded enzymes. AIM-1 (Adelaide IMipenmase 1) from Pseudomonas aeruginosa was the first B3 MBL to be identified on a readily mobile genetic element. Here we present the crystal structure of AIM-1 and use in silico docking and quantum mechanics and molecular mechanics (QM/MM) calculations, together with site-directed mutagenesis, to investigate its interaction with -lactams. AIM-1 adopts the characteristic ␣/␣ sandwich fold of MBLs but differs from other B3 enzymes in the conformation of an active site loop (residues 156 to 162) which is involved both in disulfide bond formation and, we suggest, interaction with substrates. The structure, together with docking and QM/MM calculations, indicates that the AIM-1 substrate binding site is narrower and more restricted than those of other B3 MBLs, possibly explaining its higher catalytic efficiency. The location of Gln157 adjacent to the AIM-1 zinc center suggests a role in drug binding that is supported by our in silico studies. However, replacement of this residue by either Asn or Ala resulted in only modest reductions in AIM-1 activity against the majority of -lactam substrates, indicating that this function is nonessential. Our study reveals AIM-1 to be a subclass B3 MBL with novel structural and mechanistic features. -Lactams are the most commonly used antibiotics globally (3, 58, 59), but the dissemination and increased prevalence of -lactamases worldwide have seriously challenged their clinical effectiveness. -Lactamases cleave the -lactam ring by hydrolysis, inactivating the antibiotic. To date, more than 890 such enzymes have been discovered (6, 7). Metallo--lactamases (MBLs) are a distinct group of -lactamases found in many clinically relevant Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumannii, and various Enterobacteriaceae (37). In addition, MBLs have been discovered in a range of environmental and clinically innocuous bacteria (2, 59, 61). The hydrolytic spectrum of MBLs includes all -lactams, with the exception of monobactams (aztreonam) (59), and they are not inhibited by serine -lactamase inhibitors, such as clavulanic acid, tazobactam, and sulbactam, in clinical use (19,33,45).MBLs are divided into three subclasses (B1, B2, and B3) on the basis of sequence similarity and structural features (2). Prior to the identification of AIM-1 (Adelaide IMipenmase 1) in P. aeruginosa (63) and the recently published SMB-1 (57), other acquired or mobile MBLs (IMPs, VIMs, NDMs, SPM, GIM, SIM, DIM, TMB-1, and KHM-1) (58) were almost exclusively confined to the B1 subclass. AIM-1 belongs to subclass B3 and was the first such enzyme to be found on a mobile genetic element from a major...